• DIDS: Mechanism, Evidence, and Research Use

  2026-09-27

  DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is an anion-transport research tool with reported effects on chloride transport, TRPV1 currents, and vascular smooth muscle. This evidence guide separates reported assay findings from practical limits and from metastasis research in which DIDS was used in a distinct cell-survival context.

• Fluorescein TSA Fluorescence System Kit for HCC

  2026-09-26

  Map low-abundance HCC targets such as SCD1 and CD36 with spatially resolved fluorescence amplification, or adapt the same HRP-based chemistry for cellular assays and RNA in situ hybridization. This practical guide separates findings from the miR-3180 study from proposed TSA follow-up experiments, with pilot conditions and troubleshooting advice for assay development.

• SNS-032: Reading CDK9 Through RNA Pol II

  2026-09-25

  SNS-032 (BMS-387032) links CDK inhibition to measurable changes in RNA polymerase II phosphorylation. This article explains how to interpret those changes in cancer research—and why a SARS-CoV-2 release study offers a useful, but carefully bounded, perspective on CDK9 biology.

• 5-(N,N-dimethyl)-Amiloride in Endothelial Studies

  2026-09-25

  Use 5-(N,N-dimethyl)-Amiloride hydrochloride to test whether Na+/H+ exchange contributes to pH shifts and barrier changes in endothelial injury models. Paired with moesin, signaling, and permeability readouts, it adds a functional ion-transport perturbation—but does not substitute for the direct moesin-silencing evidence in the sepsis study.

• SW033291: 15-PGDH Inhibitor Workflows

  2026-09-24

  Use SW033291 to connect 15-PGDH target engagement with PGE2 measurements and functional regeneration readouts. This workflow guide also shows how to investigate muscle repair during GLP-1 receptor agonist–associated weight loss—while keeping the reference study’s findings distinct from compound-specific evidence.

• CHIR-99021 and the Timing of Neuronal Maturation

  2026-09-24

  CHIR-99021 (CT99021) is widely used to manipulate GSK-3 signaling during stem-cell differentiation. This article examines a less explored question: how to distinguish an early pathway response from the later, post-transcriptionally controlled events that establish neuronal axon identity.

• DIDS: Applied Workflows for Channel and Cancer Studies

  2026-09-23

  DIDS offers a practical way to perturb anion transport in channel, smooth-muscle, and cell-stress experiments—but its broad pharmacology makes orthogonal controls essential. This guide turns reported potency data and a metastasis-related cell-survival study into cautious, testable workflows, with solubility and interpretation checks built in.

• EZH2 Maintains the Epithelial State in Breast Cancer

  2026-09-23

  This preprint identifies an unexpected function for EZH2 in breast carcinoma: rather than simply promoting dissemination, EZH2 represses mesenchymal genes and helps cells remain toward the epithelial end of the EMT spectrum. Using reversible TGF-β-induced EMT, pharmacological EZH2 inhibition, and human tumor analyses, the study proposes a conserved PRC2 mechanism with implications for cancer epigenetics research and therapeutic interpretation.

• Cimetidine: H2R Biology and BBB Assay Strategy

  2026-09-22

  Cimetidine is a histamine-2 receptor antagonist with partial H2 receptor activity and a pharmacological profile distinct from ranitidine and famotidine. Its product properties support controlled receptor, cancer research, and BBB assay workflows, but the cited BBB study does not establish clinical brain exposure.

• Viral RIPK3 Degradation Controls Inflammation

  2026-09-22

  Liu and colleagues identified a viral inducer of RIPK3 degradation, or vIRD, that connects orthopoxvirus immune evasion with SCF-dependent proteolysis and necroptotic inflammation. The study combines screening, biochemical validation, engineered viruses, and mouse genetics to show that vIRD can reshape viral replication, inflammation, and disease severity.

• LGK-974: A Translational Map for PORCN Inhibition

  2026-09-21

  LGK-974 is a potent PORCN inhibitor that suppresses Wnt ligand maturation and secretion upstream of receptor engagement. This thought-leadership analysis connects its use in Wnt-dependent cancer models with emerging evidence in sclerosteosis, offering translational researchers a framework for biomarker selection, experimental design, and cross-domain interpretation.

• SNS-032: CDK9 Signaling and Viral Egress

  2026-09-21

  SNS-032 (BMS-387032) is a selective CDK2, CDK7, and CDK9 inhibitor for dissecting transcription, cell-cycle signaling, and cancer biology. This article translates its RNA polymerase II phosphorylation profile into a practical framework for interpreting host-factor studies of SARS-CoV-2 release without conflating evidence for SNS-032 with evidence for CDKI-73.

• Amiloride (MK-870) Workflow for Ion Transport

  2026-09-20

  Amiloride (MK-870) provides a practical perturbation tool for separating epithelial sodium flux, receptor-associated signaling, and cellular uptake in mechanistic assays. This workflow also shows how to use the compound as a hypothesis-testing control when studying phosphatidylinositol nanoliposomes and cellular immunity, without assuming that the nanovaccine study directly tested amiloride.

• ARCA EGFP mRNA as a Delivery Calibration Tool

  2026-09-19

  ARCA EGFP mRNA can function as more than a transfection control: it provides a functional readout for separating nucleic-acid delivery, translation, and cell recovery. This article connects fluorescence-based transfection assays with impedance-monitored in situ electroporation to improve experimental interpretation.

• RNAi Screen Maps SARS-CoV-2 Release Factors

  2026-09-18

  Kerr et al. used an arrayed druggable-genome RNAi screen with two-timepoint viral production measurements to identify host factors acting across the SARS-CoV-2 replication cycle. The study highlights Rab11a-dependent vesicular transport as a conserved release pathway and shows that CDK9 inhibition with CDKI-73 can block viral egress, providing a mechanistic basis for host-directed antiviral investigation.

8520 records 1/568 page Next 12345 下5页 Last page